Human TRAIL R2/TNFRSF10B Antibody AF631 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman TRAIL R2/TNFRSF10B Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $479.00Supplier Page View Company Product Page
Catalog NumberAF631
ApplicationsFlow Cytometry,Immunohistochemistry,Immunoprecipitation,Western Blot,Immunohistochemistry-Paraffin,Agonist Activity,Neutralization,Immunocytochemistry,Functional Assay
Conjugate/TagUnconjugated
TargetTRAIL R2/TNFRSF10B
HostGoat
Quantity100 ug (also 25 ug)
ReactivityHuman,Mouse
IsotypeIgG
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
ClonalityPolyclonal
ImmunogenMouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B, Ala54-Glu182, Accession # Q6FH58
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution
NCBI Full Gene NameTNF receptor superfamily member 10b
NCBI Gene AliasesCD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9

Specifications/Features

Available conjugates: Unconjugated

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Activation of the integrated stress response and loss of cFLIPL under glutamine limitation induce IL-8 gene expression and secretion in glutamine-dependent tumor cellsCell Death DiscovJuly 19, 2025Rocío Mora-Molina, F. Javier Fernández-Farrán, Abelardo López-Rivas, Carmen Palaciosantibody (10835-1-AP) was purchased from Proteintech (IL, USA). Anti-TRAIL-R1 (AF347), anti-TRAIL-R2/DR5 (AF631) and recombinant TRAIL-R2-Fc chimeric protein (631-T2) were obtained from R&D Systems (Minneapolis,

(2) Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cellsCell death & diseaseOctober 27, 2022Yerbes R, Mora-Molina R, Fernández-Farrán FJ, Hiraldo L, López-Rivas A, Palacios C.(D4B8) antibodies were from Santa Cruz Biotechnology (CA, USA). Anti-TRAIL-R1 (AF347), anti-TRAIL-R2 (AF631) and Recombinant TRAIL-R2-Fc chimeric protein (631-T2) were from R&D Systems (Minneapolis, USA). Anti-c-FLIP

(3) cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cellsCell death & diseaseFebruary 3, 2022Mora-Molina R, Stöhr D, Rehm M, López-Rivas A.(SC-819) were purchased from Santa Cruz Technology (Santa Cruz, CA, USA). Anti-TRAIL-R2/DR5 antibody (AF631) was obtained from R&D Systems (Minneapolis, USA). Anti-FLIP (7F10) (ALX-804–961) antibody was from

(4) Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2eLifeJuly 5, 2021Jeong D, Kim HS, Kim HY, Kang MJ, Jung H, Oh Y, Kim D, Koh J, Cho SY, Jeon YK, et al.hFLSCs were treated with recombinant TRAIL (200 ng/mL or as indicated; R and D Systems) or 20 μg/mL AF631 anti-DR5 neutralizing polyclonal antibodies (R and D Systems) 1 hr prior to FasL treatment. U0126 (ERK),

(5) Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer ModelsInternational journal of molecular sciencesMarch 19, 2021Kopczynski M, Statkiewicz M, Cybulska M, Kuklinska U, Unrug-Bielawska K, Sandowska-Markiewicz Z, Grochowska A, Gajewska M, Kulecka M, Ostrowski J, et al.The following antibodies were used: TNFRSF10A (AF347, R&D Systems, Minneapolis, MN, USA), TNFRSF10B (AF631, R&D Systems, Minneapolis, MN, USA), TNFRSF10C (AF630, R&D Systems, Minneapolis, MN, USA), and TNFRSF10D

(6) Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomasScientific reportsMarch 18, 2021An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, Cheng H, Silvin C, Yang X, Van Waes C, et al.

(7) Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial gliomaOncology reportsMarch 1, 2021Park SA, Han HR, Ahn S, Ryu CH, Jeun SS.were harvested and incubated with phycoerythrin-conjugated anti human DR5 antibody (1:1,000; cat. no. AF631; R&D Systems, Inc.), as described previously (25,26). Briefly, cells (2.5×105) were stained with the

(8) Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaCancer medicineSeptember 1, 2017Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, et al.

(9) Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cellsCell death & diseaseAugust 31, 2017Shlyakhtina Y, Pavet V, Gronemeyer H.and Abcam (Cambridge, MA, USA) (anti-EEA1 cat. AB2900). Antibodies for immunoprecipitation of DR5 (AF631), DR4 (AF347), DcR2 (AF633), TRAF2 (AF3277) and normal goat IgG (AB-108-C) were purchased from R&D Systems

(10) Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant gliomaStem cells translational medicineFebruary 1, 2014Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS.

(11) Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cellsCell death & diseaseJanuary 30, 2014Pavet V, Shlyakhtina Y, He T, Ceschin DG, Kohonen P, Perälä M, Kallioniemi O, Gronemeyer H.and cleaved caspase-8 (no. 9496) from Cell Signaling. DISC immunoprecipitation assays used anti-DR5 (AF631) purchased from R&D Systems (Minneapolis, MN, USA). Cell Lines Cells from stepwise tumorigenesis systems

(12) Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulationScience translational medicineJune 8, 2011Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS.human TRAIL was produced and purified as described previously (48). The human DR5-activating antibody, AF631, was purchased from R&D Systems. AG1478 and AG825 were purchased from Sigma. JNK2 siRNA was purchased

(13) Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cellsCellular signallingOctober 1, 2009Park SJ, Sohn HY, Yoon J, Park SI.

(14) Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIPThe Biochemical journalApril 28, 2009Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.

(15) Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathwayBiochemical pharmacologyApril 15, 2009Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.

(16) Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cellsInternational journal of oncologyAugust 1, 2008Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M.

(17) TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5Human gene therapyJuly 1, 2008Wu CH, Kao CH, Safa AR.

(18) Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulationCancer researchJanuary 1, 2008Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS.

(19) Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivoInternational journal of oncologyDecember 1, 2007Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M.

(20) P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5Biochemical pharmacologyJuly 28, 2006Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.

Be the First to Write a Review!

TRAIL R2/TNFRSF10B Antibody

TRAIL R2/TNFRSF10B Antibody

Human TRAIL R2/TNFRSF10B Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (34)

Reviews

Human TRAIL R2/TNFRSF10B Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map